U.S. International Trade Commission Updates Case on C-Type Natriuretic Peptide Drug Products

Estimated reading time: 1–3 minutes

The U.S. International Trade Commission has provided an update on an ongoing investigation regarding certain drug products. These drug products contain C-Type Natriuretic Peptide variants and their components.

This investigation was started on May 8, 2025. It was based on a complaint from BioMarin Pharmaceutical Inc. This company is located in Novato, California. The complaint claimed violations of a law called Section 337 of the Tariff Act of 1930. The violations were about importing certain drug products into the United States. These products allegedly infringed claims of a specific patent known as RE’267.

The investigation identified several respondents. They include Ascendis Pharma, Inc., now known as Ascendis Pharma, LLC. Other respondents come from Denmark and Germany. The Office of Unfair Import Investigations is also part of this process.

There were some changes during the investigation. On April 14, 2026, BioMarin asked to update the complaint. This request was about the name change of one respondent. The new name is Ascendis Pharma, LLC. This update was approved by the Chief Administrative Law Judge on April 27, 2026.

The Commission decided not to review this name change. This decision was made on May 15, 2026. The investigation notice now correctly shows the new name for Ascendis Pharma.

The investigation continues under the regulations of the Tariff Act of 1930 and the Commission’s Rules of Practice and Procedure. More updates will be provided as the case develops.

Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.